Dare Bioscience (DARE) Set to Announce Quarterly Earnings on Tuesday

Dare Bioscience (NASDAQ:DARE) is scheduled to be issuing its quarterly earnings data before the market opens on Tuesday, November 13th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter.

Dare Bioscience (NASDAQ:DARE) last posted its quarterly earnings results on Monday, August 13th. The biotechnology company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.09). On average, analysts expect Dare Bioscience to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

DARE stock opened at $0.93 on Friday. The company has a market cap of $10.39 million, a price-to-earnings ratio of -0.75 and a beta of 2.37. Dare Bioscience has a one year low of $0.74 and a one year high of $3.59.

DARE has been the topic of several research reports. Maxim Group initiated coverage on shares of Dare Bioscience in a research note on Friday, August 17th. They set a “buy” rating and a $3.00 price target on the stock. ValuEngine raised shares of Dare Bioscience from a “hold” rating to a “buy” rating in a research note on Tuesday, October 2nd.

ILLEGAL ACTIVITY NOTICE: This piece was originally published by WKRB News and is owned by of WKRB News. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.wkrb13.com/2018/11/11/dare-bioscience-dare-set-to-announce-quarterly-earnings-on-tuesday.html.

About Dare Bioscience

Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder.

Featured Story: Understanding Market Liquidity

Earnings History for Dare Bioscience (NASDAQ:DARE)

Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply